Nephronophthisis (NPH) is a recessive cystic kidney disease responsible for 10% to 20% of pediatric end-stage renal disease cases. NPHP1 (nephrocystin 1) is the most frequently implicated among over ...

California-based Vivace Therapeutics has announced the closing of a $35 million Series D financing. The proceeds will support the continued clinical development of the company's first-in-class and ...

VT3989 is a transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor that blocks the palmitoylation of TEAD protein family members to target the Hippo pathway. RA Capital ...

Financing Led by RA Capital Management with Participation from Other Existing Investors Canaan Partners and Cenova Capital VT3989 is the Only TEAD Autopalmitoylation Inhibitor ...

Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...

Among these signals, the TGF-β and HIPPO pathways are critical, functioning as tumor suppressors and regulating liver development and regeneration. The review focuses on these pathways' interplay ...

The expansion of the Salvador (SAV)–Warts (WTS)–Hippo (HPO) pathway continues with three recent papers that extend the list of upstream regulators and identify links to Wnt signalling.

The lab reported in the journal Science that a gene pathway called Hippo inhibits cardiac muscle regeneration during development. View the Science Journal article. Our lab is currently working to ...